Evidence map›Paper›PMID 33344504›Full record

ArticleFrontiers in molecular biosciences2020

Insulin-Regulated Aminopeptidase Inhibition Ameliorates Metabolism in Obese Zucker Rats.

Katarina Krskova, Lucia Balazova, Viktoria Dobrocsyova, Rafal Olszanecki, Maciej Suski, Siew Yeen Chai, Štefan Zorad

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Katarina KrskovaInstitute of Experimental Endocrinology, Biomedical Research Center, Department of Endocrine Regulations and Psychofarmacology, Slovak Academy of Sciences, Bratislava, Slovakia.
Lucia BalazovaInstitute of Experimental Endocrinology, Biomedical Research Center, Department of Endocrine Regulations and Psychofarmacology, Slovak Academy of Sciences, Bratislava, Slovakia.
Viktoria DobrocsyovaInstitute of Experimental Endocrinology, Biomedical Research Center, Department of Endocrine Regulations and Psychofarmacology, Slovak Academy of Sciences, Bratislava, Slovakia.
Rafal OlszaneckiDepartment of Pharmacology, Jagiellonian University Medical College, Cracow, Poland.
Maciej SuskiDepartment of Pharmacology, Jagiellonian University Medical College, Cracow, Poland.
Siew Yeen ChaiMonash Biomedicine Discovery Institute, Department of Physiology, Monash University, Clayton, VIC, Australia.
Štefan ZoradInstitute of Experimental Endocrinology, Biomedical Research Center, Department of Endocrine Regulations and Psychofarmacology, Slovak Academy of Sciences, Bratislava, Slovakia.
Institute of Experimental Endocrinology of the Slovak Academy of Sciences · SKJagiellonian University · PLMonash University · AUSlovak Academy of Sciences · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of our study was to determine the influence of inhibition of insulin-regulated aminopeptidase/oxytocinase (IRAP) on glucose tolerance and metabolism of skeletal muscle and visceral adipose tissue in obese Zucker rats. Obese Zucker rats administered with IRAP inhibitor-HFI-419 at a dose of 29 μg/100 g BW/day by osmotic minipumps implanted subcutaneously for 2 weeks. Two-hour intraperitoneal glucose tolerance test (ipGTT) was performed in fasting rats. Plasma oxytocin levels were measured by enzyme immunoassay after plasma extraction. In the musculus quadriceps and epididymal adipose tissue, the expression of factors affecting tissue oxidative status and metabolism was determined by real-time qPCR and/or Western blot analysys. The plasma and tissue enzymatic activities were determined by colorimetric or fluorometric method. Circulated oxytocin levels in obese animals strongly tended to increase after HFI-419 administration. This was accompanied by significantly improved glucose utilization during ipGTT and decreased area under the curve (AUC) for glucose. In skeletal muscle IRAP inhibitor treatment up-regulated enzymes of antioxidant defense system - superoxide dismutase 1 and 2 and improved insulin signal transduction pathway. HFI-419 increased skeletal muscle aminopeptidase A expression and activity and normalized its plasma levels in obese animals. In epididymal adipose tissue, gene expression of markers of inflammation and adipocyte hypertrophy was down-regulated in obese rats after HFI-419 treatment. Our results demonstrate that IRAP inhibition improves whole-body glucose tolerance in insulin-resistant Zucker fatty rats and that this metabolic effect of HFI-419 involves ameliorated redox balance in skeletal muscle.

Indexed as

HFI-419insulin-regulated aminopeptidaseinsulin resistanceIRAPobesity

Identifiers

PMID33344504
PMCPMC7746680
OpenAlexW3108506264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.